These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36417082)

  • 1. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
    McCurdy A; Visram A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):306-318. PubMed ID: 36417082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
    Joseph NS; Tai YT; Anderson KC; Lonial S
    Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
    Prawitz T; Popat R; Suvannasankha A; Sarri G; Hughes R; Wang F; Hogea C; Ferrante SA; Gorsh B; Willson J; Kapetanakis V
    Adv Ther; 2021 Nov; 38(11):5501-5518. PubMed ID: 34561812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.
    Neupane K; Wahab A; Masood A; Faraz T; Bahram S; Ehsan H; Hannan A; Anwer F
    J Blood Med; 2021; 12():529-550. PubMed ID: 34234609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belantamab mafodotin for the treatment of multiple myeloma.
    Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
    Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.
    Lassiter G; Bergeron C; Guedry R; Cucarola J; Kaye AM; Cornett EM; Kaye AD; Varrassi G; Viswanath O; Urits I
    Curr Oncol; 2021 Jan; 28(1):640-660. PubMed ID: 33494319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates in the management of relapsed/refractory multiple myeloma.
    Hanna KS; Larson S; Nguyen J; Tu S; Boudreau J; Rose S
    J Oncol Pharm Pract; 2021 Sep; 27(6):1477-1490. PubMed ID: 34162244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
    Becnel MR; Lee HC
    Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
    Nooka AK; Weisel K; van de Donk NW; Routledge D; Otero PR; Song K; Quach H; Callander N; Minnema MC; Trudel S; Jackson NA; Ahlers CM; Im E; Cheng S; Smith L; Hareth N; Ferron-Brady G; Brouch M; Montes de Oca R; Paul S; Holkova B; Gupta I; Kremer BE; Richardson P
    Future Oncol; 2021 Jun; 17(16):1987-2003. PubMed ID: 33682447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
    Shah A; Tosh JC; Ambavane A; Nikolaou A; Hogea C; Samyshkin Y; Gorsh B; Maiese EM; Wang F
    Clinicoecon Outcomes Res; 2021; 13():789-800. PubMed ID: 34531667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Belantamab Mafodotin on Primary Myeloma-Stroma Co-Cultures: Asymmetrical Mitochondrial Transfer between Myeloma Cells and Autologous Bone Marrow Stromal Cells.
    Matula Z; Uher F; Vályi-Nagy I; Mikala G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melflufen for relapsed and refractory multiple myeloma.
    Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
    Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
    Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
    Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
    Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; Suvannasankha A; Samyshkin Y
    Expert Rev Hematol; 2021 Dec; 14(12):1137-1145. PubMed ID: 34465265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.